molecules

molecules

molecules

molecules

molecules

molecules

Clinical Pipeline

ONCOLOGY

CASDATIFAN (CAS)*

HIF-2α INHIBITOR SMALL-MOLECULE

Post-IO Kidney Cancer (ccRCC)

arc 20

1L, 2L+ Kidney Cancer (ccRCC)

QUEMLICLUSTAT (QUEMLI)^†

CD73 INHIBITOR SMALL-MOLECULE

1L Pancreatic Cancer

DOMVANALIMAB (DOM)^†

FC-SILENT ANTI-TIGIT ANTIBODY

Stage III, Unresectable, PD-L1≥1% Lung Cancer

INFLAMMATION & IMMUNOLOGY

AB102^‡

MRGPRX2 SMALL-MOLECULE ANTAGONIST

Potential Indications: Atopic Dermatitis, Chronic Spontaneous Urticaria

TNF^‡

SMALL-MOLECULE INHIBITOR

Potential Indications: Rheumatoid Arthritis, Psoriasis, Inflammatory Bowel Disease

CCR6

SMALL-MOLECULE ANTAGONIST

Potential Indications: Psoriasis

ANTI-CD89

MONOCLONAL ANTIBODY

Potential Indications: Rheumatoid Arthritis

CD40L

SMALL-MOLECULE INHIBITOR

Potential Indications: Multiple Sclerosis, Systemic Lupus Erythematosus

ONCOLOGY

CASDATIFAN (CAS)*

HIF-2α INHIBITOR SMALL-MOLECULE

Pre-Clinical Phase 1/1b Phase 2 Phase 3

Post-IO Kidney Cancer (ccRCC)
1L, 2L+ Kidney Cancer (ccRCC)

QUEMLICLUSTAT (QUEMLI)^†

CD73 INHIBITOR SMALL-MOLECULE

Pre-Clinical Phase 1/1b Phase 2 Phase 3

1L Pancreatic Cancer

DOMVANALIMAB (DOM)^†

FC-SILENT ANTI-TIGIT ANTIBODY

Pre-Clinical Phase 1/1b Phase 2 Phase 3

Stage III, Unresectable, PD-L1≥1% Lung Cancer

INFLAMMATION & IMMUNOLOGY

AB102^‡

MRGPRX2 SMALL-MOLECULE ANTAGONIST

Pre-Clinical Phase 1/1b Phase 2 Phase 3

Potential Indications: Atopic Dermatitis, Chronic Spontaneous Urticaria

TNF^‡

SMALL-MOLECULE INHIBITOR

Pre-Clinical Phase 1/1b Phase 2 Phase 3

Potential Indications: Rheumatoid Arthritis, Psoriasis, Inflammatory Bowel Disease

CCR6

SMALL-MOLECULE ANTAGONIST

Pre-Clinical Phase 1/1b Phase 2 Phase 3

Potential Indications: Psoriasis

ANTI-CD89

MONOCLONAL ANTIBODY

Pre-Clinical Phase 1/1b Phase 2 Phase 3

Potential Indications: Rheumatoid Arthritis

CD40L

SMALL-MOLECULE INHIBITOR

Pre-Clinical Phase 1/1b Phase 2 Phase 3

Potential Indications: Multiple Sclerosis, Systemic Lupus Erythematosus

KEY CANDIDATES BEING STUDIED:

CAS

Casdatifan

HIF-2𝛂 Inhibitor Small-Molecule

Quemli

Quemliclustat

CD73 Inhibitor Small-Molecule

Dom

Domvanalimab

FC-Silent Anti-TIGIT Antibody

*Taiho has development and commercial rights in Japan and other countries in Asia, excluding China, for casdatifan (the “Taiho Territory”).

^†If approved, Gilead and Arcus will share co-promotion rights in the U.S. and Gilead holds commercialization rights outside of the U.S. subject to Taiho’s rights for the Taiho Territory.

^‡Gilead retains/holds time-limited option rights.

Partnerships & Collaborations

Taiho

Astra Zeneca

For collaboration inquires, please contact [email protected]

Explore More